Group 1 - The company has agreed to acquire 1,623 ordinary shares of China Gene, representing 16.23% of its issued share capital, for a total cash consideration of HKD 43 million [1] - China Gene's main subsidiary, Huaxin, focuses on the research, production, and sales of biopharmaceutical products, particularly in gynecology and gene cell therapy [1] - The acquisition is seen as a strategic investment that will allow the company to expand its market presence in the healthcare and biopharmaceutical sectors in China, which are expected to grow significantly [2][3] Group 2 - The board believes that the acquisition will create potential long-term value and enhance the company's revenue through collaboration in the distribution of China Gene's biopharmaceutical products [2] - China Gene plans to adopt a dividend policy, aiming to distribute at least one-third of its after-tax profits after necessary provisions, which is expected to provide positive financial returns for the company [3] - The company currently has no plans or intentions for further acquisitions of China Gene's shares in the foreseeable future [4]
EPS创健科技拟4300万港元收购中国基因16.23%已发行股份